Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK-kappa B/MAPK Signaling Pathways
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jeong-In | - |
dc.contributor.author | Song, Kyung-Hee | - |
dc.contributor.author | Jung, Seung-Youn | - |
dc.contributor.author | Ahn, Jiyeon | - |
dc.contributor.author | Hwang, Sang-Gu | - |
dc.contributor.author | Kim, Joon | - |
dc.contributor.author | Kim, Eun Ho | - |
dc.contributor.author | Song, Jie-Young | - |
dc.date.accessioned | 2021-09-01T09:37:50Z | - |
dc.date.available | 2021-09-01T09:37:50Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-08-09 | - |
dc.identifier.issn | 1533-0346 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/63542 | - |
dc.description.abstract | Objective: Tumor-treating fields are currently used to successfully treat various cancers; however, the specific pathways associated with its efficacy remain unknown in the immune responses. Here, we evaluated tumor-treating fields-mediated initiation of the macrophage-specific immune response. Materials and Methods: We subjected RAW 264.7 mouse macrophages to clinically relevant levels of tumor-treating fields (0.9 V/cm, 150 kHz) and evaluated alterations in cytokine expression and release, as well as cell viability. Additionally, we investigated the status of immunomodulatory pathways to determine their roles in tumor-treating fields-mediated immune activation. Results and Discussion: Our results indicated that tumor-treating fields treatment at 0.9 V/cm decreased cell viability and increased cytokine messenger RNA/protein levels, as well as levels of nitric oxide and reactive oxygen species, relative to controls. The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6 were markedly increased in tumor-treating fields-treated RAW 264.7 cells cocultured with 4T1 murine mammary carcinoma cells compared with those in 4T1 or RAW 264.7 cells with or without tumor-treating fields treatment. Moreover, the viability of 4T1 cells treated with the conditioned medium of tumor-treating fields-stimulated RAW 264.7 cells decreased, indicating that macrophage activation by tumor-treating fields effectively killed the tumor cells. Moreover, tumor-treating fields treatment activated the nuclear factor kappa B and mitogen-activated protein kinase pathways involved in immunomodulatory signaling. Conclusion: These results provide critical insights into the mechanisms through which tumor-treating fields affect macrophage-specific immune responses and the efficacy of this method for cancer treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS INC | - |
dc.subject | NITRIC-OXIDE | - |
dc.subject | CELL-ADHESION | - |
dc.subject | IN-VITRO | - |
dc.subject | CANCER | - |
dc.subject | MAPK | - |
dc.subject | EXPRESSION | - |
dc.subject | POLYSACCHARIDE | - |
dc.subject | GLIOBLASTOMA | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | INFLAMMATION | - |
dc.title | Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK-kappa B/MAPK Signaling Pathways | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Joon | - |
dc.identifier.doi | 10.1177/1533033819868225 | - |
dc.identifier.scopusid | 2-s2.0-85071281810 | - |
dc.identifier.wosid | 000481869900002 | - |
dc.identifier.bibliographicCitation | TECHNOLOGY IN CANCER RESEARCH & TREATMENT, v.18 | - |
dc.relation.isPartOf | TECHNOLOGY IN CANCER RESEARCH & TREATMENT | - |
dc.citation.title | TECHNOLOGY IN CANCER RESEARCH & TREATMENT | - |
dc.citation.volume | 18 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | NITRIC-OXIDE | - |
dc.subject.keywordPlus | CELL-ADHESION | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | MAPK | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | POLYSACCHARIDE | - |
dc.subject.keywordPlus | GLIOBLASTOMA | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordAuthor | TTFs | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | immune | - |
dc.subject.keywordAuthor | cytokine | - |
dc.subject.keywordAuthor | MAPK | - |
dc.subject.keywordAuthor | NF-kappa B | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.